Trexquant Investment LP Makes New Investment in Organogenesis $ORGO

Trexquant Investment LP acquired a new position in Organogenesis (NASDAQ:ORGO - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 119,359 shares of the company's stock, valued at approximately $516,000. Trexquant Investment LP owned 0.09% of Organogenesis at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its stake in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after acquiring an additional 4,239 shares during the period. CWM LLC lifted its stake in Organogenesis by 8.9% in the first quarter. CWM LLC now owns 63,894 shares of the company's stock valued at $276,000 after purchasing an additional 5,239 shares during the last quarter. Millennium Management LLC raised its position in Organogenesis by 2.8% during the fourth quarter. Millennium Management LLC now owns 208,420 shares of the company's stock valued at $667,000 after purchasing an additional 5,765 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Organogenesis by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after purchasing an additional 6,689 shares during the last quarter. Finally, Merit Financial Group LLC bought a new stake in shares of Organogenesis in the 1st quarter worth approximately $45,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ORGO. Cantor Fitzgerald upped their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. BTIG Research restated a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

Organogenesis Stock Performance

NASDAQ ORGO traded down $0.11 on Friday, reaching $4.93. The company's stock had a trading volume of 731,186 shares, compared to its average volume of 742,392. The firm's 50 day moving average is $4.70 and its two-hundred day moving average is $4.29. The stock has a market cap of $625.41 million, a PE ratio of -35.21 and a beta of 1.75. Organogenesis has a twelve month low of $2.61 and a twelve month high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The firm had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.